Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX Luminal B neoadjuvant response-guided therapy in ER-positive early breast cancer
2024-519019-32-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of palbociclib in breast cancer (3 arms), sponsored by Karolinska University Hospital. Primary endpoint: Clinical and radiological objective response after 12 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519019-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519019-32-00.